Wegovy vs Mounjaro: Switching Between Them

How Wegovy and Mounjaro Work Differently

Wegovy and Mounjaro share GLP-1 receptor activation but diverge at a second target. That difference in receptor pharmacology explains much of the gap in clinical outcomes between the two drugs.

Wegovy contains semaglutide at 2.4 mg, a selective GLP-1 receptor agonist. It slows gastric emptying, suppresses glucagon secretion, and acts on hypothalamic appetite centers to reduce caloric intake. The FDA approved Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1].

Mounjaro contains tirzepatide, which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds distinct effects on fat metabolism and insulin sensitivity that semaglutide does not produce. In preclinical models, dual agonism improved lipid handling in adipose tissue and amplified the incretin effect beyond what GLP-1 alone achieves [2]. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity noted that "tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrated the largest magnitude of weight reduction among currently approved anti-obesity medications" [3].

This mechanistic distinction matters for patients considering a switch. A person who responds well to GLP-1 agonism alone may not need the additional GIP pathway. A person who has plateaued on semaglutide could potentially benefit from the added GIP-mediated effects of tirzepatide.

Weight-Loss Results: Key and Head-to-Head Trials

Tirzepatide produced greater weight loss than semaglutide 2.4 mg in the only completed head-to-head trial. Cross-trial comparisons of their key studies pointed in the same direction, though with caveats about differing study populations.

In STEP-1 (N=1,961), participants without diabetes received semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost 14.9% of body weight compared with 2.4% in the placebo arm. About 86% of semaglutide-treated participants lost at least 5% of their body weight [4].

In SURMOUNT-1 (N=2,539), participants without diabetes received tirzepatide at 5, 10, or 15 mg or placebo for 72 weeks. Weight loss was 15.0% with the 5 mg dose, 19.5% with 10 mg, and 22.5% with 15 mg, versus 3.1% with placebo. More than half of participants on the 10 mg and 15 mg doses achieved at least 20% weight reduction [5].

These trials cannot be directly compared. Population BMIs, geographic distributions, and background lifestyle interventions differed. That gap was closed by SURMOUNT-5, a randomized, open-label trial (N=751) that directly compared tirzepatide (titrated to the maximum tolerated dose of 10 or 15 mg) against semaglutide 2.4 mg over 72 weeks. Tirzepatide-treated participants lost 20.2% of body weight versus 13.7% with semaglutide. The estimated treatment difference was 6.5 percentage points (95% CI, 5.1 to 7.9; P<0.001) [6].

Dr. Ania Jastreboff, lead investigator of the SURMOUNT program at Yale, stated that "the magnitude of weight reduction with tirzepatide in SURMOUNT-5 exceeded that of semaglutide 2.4 mg by a clinically meaningful margin across prespecified subgroups" [6].

For patients deciding between these drugs or considering a switch, this trial provides the most relevant data available. Tirzepatide produced roughly 47% more relative weight loss than semaglutide at maximum doses over the same timeframe.

When Clinicians Recommend Switching

A switch between these medications is not a failure. It is a standard clinical decision triggered by specific, measurable criteria.

The three most common reasons prescribers initiate a switch are:

Weight-loss plateau. If a patient on maximally titrated semaglutide 2.4 mg has not lost at least 5% of baseline body weight after 16 to 24 weeks at the full dose, the American Gastroenterological Association's 2022 guideline recommends reassessing the pharmacotherapy regimen [7]. A plateau at a submaximal dose, in contrast, should prompt continued titration before considering a drug change.

Intolerable GI side effects. Persistent nausea, vomiting, or diarrhea that does not resolve despite slower titration and dietary modifications can justify switching. Some patients who cannot tolerate one GLP-1 agonist tolerate the other. The side-effect profiles overlap but are not identical because of tirzepatide's additional GIP activity, which may modulate gastric motility differently in some individuals.

Insurance or cost barriers. Formulary changes can force a switch in either direction. A plan that covered Wegovy in 2024 might move to preferred coverage of Zepbound (the obesity-indication brand of tirzepatide) in 2025, or the reverse. Out-of-pocket costs without coverage can exceed $1,300 per month for either drug, making formulary status a practical determinant of which medication a patient receives [8].

Less common but valid reasons include a desire for the dual-agonist mechanism after suboptimal response to GLP-1 alone, or a patient with type 2 diabetes whose glycemic control has worsened and who might benefit from tirzepatide's superior A1C-lowering profile demonstrated in SURPASS-2 [2].

How to Switch: Dose Mapping and Titration Protocol

No FDA-approved switching protocol exists for transitioning between semaglutide and tirzepatide. Clinical practice relies on consensus guidance and label-directed titration schedules.

The standard approach is straightforward. Stop the outgoing drug after the last scheduled weekly injection, then start the incoming drug at its lowest titration dose one week later. There is no pharmacological requirement for a washout period between the two medications, as neither drug has active metabolites that interact with the other.

For a Wegovy to Mounjaro/Zepbound switch, the patient discontinues semaglutide 2.4 mg and starts tirzepatide at 2.5 mg weekly. The tirzepatide titration schedule proceeds as labeled: 2.5 mg for 4 weeks, then 5 mg for 4 weeks, with subsequent 2.5 mg increases every 4 weeks until the target dose (up to 15 mg) is reached [9].

For a Mounjaro/Zepbound to Wegovy switch, the patient discontinues tirzepatide and starts semaglutide at 0.25 mg weekly. The Wegovy titration takes 16 weeks to reach the maintenance dose: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg ongoing [1].

Some clinicians compress the early titration steps when switching from a high-dose GLP-1 agonist, reasoning that the patient already has established GLP-1-mediated GI adaptation. This is an off-label practice. The 2024 Endocrine Society guideline did not endorse accelerated titration but acknowledged that "titration speed may be individualized based on tolerability" [3].

Restarting titration from the bottom means patients will temporarily experience less appetite suppression than they had at their prior maintenance dose. Weight regain during the titration-up period is possible and should be discussed in advance so it does not trigger premature discontinuation.

Side Effects to Expect After Switching

GI symptoms are the dominant concern during any GLP-1 agonist transition. Both drugs cause nausea, diarrhea, vomiting, and constipation at similar overall rates, but the timing and intensity after a switch can differ from what the patient experienced during initial treatment.

In STEP-1, nausea occurred in 44.2% of semaglutide-treated participants, most commonly during the dose-escalation phase. Diarrhea occurred in 31.5%, and vomiting in 24.8% [4]. In SURMOUNT-1, nausea rates were 24.6% (5 mg), 33.3% (10 mg), and 31.0% (15 mg). Diarrhea rates ranged from 18.7% to 21.2% across tirzepatide doses [5]. These numbers are not directly comparable because of different titration speeds and patient populations, but they suggest similar GI burden in aggregate.

After switching, patients commonly report a "second wave" of GI symptoms during titration of the new drug, even if they had long since adapted to the prior medication. The GIP receptor activation unique to tirzepatide can produce different patterns of nausea and satiety signaling, so a patient switching from Wegovy to tirzepatide may notice changes in meal tolerance, early satiety timing, or stool consistency that differ from their semaglutide experience.

Non-GI effects also warrant monitoring. Both drugs carry FDA boxed warnings for medullary thyroid carcinoma risk based on rodent studies [1][9]. Tirzepatide-treated patients in SURPASS trials showed slightly higher rates of cholelithiasis than semaglutide patients in STEP trials, though this may reflect faster weight loss rather than a direct pharmacological effect [2][4].

Injection-site reactions (redness, itching, or swelling) may differ between the two drugs because of their distinct formulations and injection devices. Patients who had no injection-site issues with the semaglutide autoinjector may experience mild reactions with the tirzepatide pen, or vice versa.

Insurance, Cost, and Formulary Barriers

Drug cost is frequently the deciding factor in a Wegovy-to-Mounjaro switch, or the reverse. Both drugs carry list prices above $1,000 per month, and coverage varies dramatically by payer.

Wegovy's wholesale acquisition cost is approximately $1,349 per month at the 2.4 mg maintenance dose. Zepbound (tirzepatide for obesity) lists at approximately $1,059 per month, though both manufacturers offer savings programs for commercially insured patients that can reduce copays to $25 to $500 per month depending on plan design [8].

Medicare Part D does not cover anti-obesity medications. This exclusion affects roughly 67 million enrollees. The Treat and Reduce Obesity Act, if passed, would change this, but as of May 2026 it has not been enacted.

For commercially insured patients, formulary tier placement determines practical access. Some plans cover Wegovy but not Zepbound; others list tirzepatide products but exclude semaglutide for weight management. Prior authorization is required by the majority of commercial payers for both drugs, and step therapy requirements (such as documented failure of a lower-cost GLP-1 agonist like liraglutide) are common.

When insurance forces a switch, the prescriber should document the clinical rationale for the new medication and submit prior authorization with supporting lab work, documented weight-loss trajectory, and a record of adverse effects on the prior drug if applicable. A peer-to-peer review with the payer's medical director may be needed.

Monitoring and Follow-Up After Switching

A switch between GLP-1 agonists requires closer follow-up than maintenance on a stable regimen. The first 12 weeks after starting the new drug are the highest-risk period for side effects, weight regain, and patient dropout.

Recommended monitoring schedule after switching:

Baseline labs should be obtained within 2 weeks before or after the switch. These include fasting glucose or HbA1c, lipid panel, hepatic function panel, and renal function (eGFR and serum creatinine). In patients with type 2 diabetes, more frequent glucose monitoring is needed because switching GLP-1 agonists can alter insulin sensitivity and hypoglycemia risk, particularly if the patient also takes a sulfonylurea or insulin [3].

Follow-up visits at 4 weeks, 8 weeks, and 12 weeks allow the clinician to assess GI tolerability, guide titration speed, and intervene early if weight regain exceeds 2 to 3% of body weight. After 12 weeks, follow-up can return to the standard quarterly schedule.

Body composition assessment (via DEXA or bioimpedance) at baseline and at 6 months post-switch can identify whether weight loss is predominantly fat mass, which is the desired outcome, or includes disproportionate lean mass loss. In SURMOUNT-1, approximately 25 to 30% of total weight lost with tirzepatide was lean mass, a ratio comparable to that seen with semaglutide in STEP-1 [4][5].

Patients should be counseled that the full effect of the new medication will not be apparent until they reach and maintain the target dose for at least 12 weeks. The AGA guideline defines treatment response as at least 5% body-weight loss from the pre-treatment baseline within 12 to 16 weeks at the maintenance dose [7].

Pancreatitis screening is warranted if the patient develops severe abdominal pain during titration. While the absolute risk is low (reported at <0.5% in the key trials for both drugs), switching does not eliminate or reset this risk [4][5].